Interaction between clopidogrel and proton-pump inhibitors

References

• Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol.52(18), 1502–1517 (2008).
   PubMed Web of Science ®Google Scholar
• Plavix [package insert]. Bridgewater, NJ, Sanofi-Aventis US (2008).
   Google Scholar
• Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol.51(20), 1925–1934 (2008).
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360(4), 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet373(9660), 309–317 (2009).
   PubMed Web of Science ®Google Scholar
• PPI interactions with clopidogrel revisited. Med. Lett. Drugs Ther.51(1306), 13–14 (2009).
   Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos.32(8), 821–827 (2004).
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol. Ther.13(Suppl.) 27–36 (1999).
   PubMed Web of Science ®Google Scholar
• Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation119, 2625–2632 (2009).
   PubMed Web of Science ®Google Scholar
• Sweeny JM, Gorog DA, and Fuster V. Antiplatelet drug ‘resistance’. Part 1: mechanisms and clinical measurements. Nat. Rev. Cardiol.6, 273–282 (2009).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL and Angiolillo DJ. Clopidogrel response variability: Current status and future directions. Thromb. Haemost.102, 7–14 (2009).
   PubMed Web of Science ®Google Scholar
• Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol.45(8), 1157–1164 (2005).
   PubMed Web of Science ®Google Scholar
• Michelson AD, Frelinger AL 3rd, Furman MI. Current options in platelet function testing. Am. J. Cardiol.98(10A), 4N–10N (2006).
   PubMed Web of Science ®Google Scholar
• Jennings LK. Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance. Crit. Pathw. Cardiol.8(1), 20–28 (2009).
   PubMedGoogle Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel. J. Am. Coll. Cardiol.49, 1505–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol.48(4), 475–484 (2008).
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Haemost.4(11), 2508–2509 (2006).
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J. Am. Coll. Cardiol.51(3), 256–260 (2008).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J.157(1), 148.e1–5 (2009).
   PubMed Web of Science ®Google Scholar
• Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am. J. Cardiol.103(10), 1339–1343 (2009).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost.101, 714–719 (2009).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J. Am. Coll. Cardiol.54(13), 1149–1153 (2009).
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis from two randomized trials. N. Engl. J. Med.374(9694), 989–997 (2009).
   Google Scholar
• Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation111(9), 1153–1159 (2005).
   PubMed Web of Science ®Google Scholar
• Roche VF. The chemically elegant proton pump inhibitors. Am. J. Pharm. Educ.70(5), 101 (2006).
   PubMed Web of Science ®Google Scholar
• Aubert RE, Epstein RS, Teagarden JR et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes study. Circulation118, S815 (2008).
   Google Scholar
• Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J. Am. Coll. Cardiol.52(12), 1038–1039 (2008).
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ180(7), 1–7 (2009).
   Google Scholar
• Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA301(9), 937–944 (2009).
   PubMed Web of Science ®Google Scholar
• Dunn SP, Macaulay TE, Brennan DM et al. Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial. Circulation118, S815 (2009).
   Google Scholar
• Rassen JA, Choudhry NK, Avorn J et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation DOI: 0:CIRCULATIONAHA.109.873497 (2009) (Epub ahead of print).
   PubMedGoogle Scholar